© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Daniel Catenacci, MD, reviews the case of a 71-year-old man with gastric cancer.
January 15th 2021
Dr Catenacci evaluates the case of a 71-year-old man with gastric cancer, and provides insight on molecular testing in gastric cancer and initial treatment options.
Daniel Catenacci, MD, discusses initial considerations for treatment in patients with microsatellite instability-high/stable, HER2-positive/negative gastric cancer and touches on second-line treatment options.
Daniel Catenacci, MD, examines factors that help decide when to switch treatment from first to second line, and when to change mechanism of action in treating gastric carcinoma.
Daniel Catenacci, MD, discusses treatment options after second-line therapy, highlighting options for patients who are PD-L1 positive.
Dr Catenacci highlights clinical trials in HER2-positive gastric cancer that may provide insight on differences in mechanism of resistance from one tumor type to another.
Dr Catenacci discusses the DESTINY-Gastric01 study, including personal experience using trastuzumab deruxtecan.